MARKET

CCXI

CCXI

ChemoCentryx
NASDAQ

Real-time Quotes | Nasdaq Last Sale

50.96
-1.87
-3.54%
After Hours: 50.96 0 0.00% 16:00 09/23 EDT
OPEN
52.20
PREV CLOSE
52.83
HIGH
54.38
LOW
50.82
VOLUME
427.33K
TURNOVER
--
52 WEEK HIGH
65.43
52 WEEK LOW
6.44
MARKET CAP
3.51B
P/E (TTM)
-93.2821
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
ChemoCentryx's NDA for Autoimmune Disease Drug Accepted by FDA
The FDA accepts ChemoCentryx's (CCXI) NDA for avacopan, for the treatment of ANCA-associated vasculitis.
Zacks · 5d ago
ChemoCentryx Announces FDA Acceptance of the Avacopan New Drug Application (NDA) for the Treatment of ANCA-Associated Vasculitis
\-- FDA sets PDUFA goal date of July 7, 2021 --MOUNTAIN VIEW, Calif., Sept. 17, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company’s New Drug Application (NDA) for avacopan, an orally-administered
GlobeNewswire · 6d ago
FDA accepts ChemoCentryx's avacopan application for blood vessel inflammation
The FDA has accepted ChemoCentryx's (CCXI) New Drug Application ((NDA)) for avacopan, an orally-administered selective complement 5a receptor inhibitor, for the treatment of ANCA-Associated Vasculitis and has set July 7, 2021
Seekingalpha · 6d ago
Hedge Funds Arent Done Buying ChemoCentryx Inc (CCXI)
At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (see why hell is coming). We reversed our stance on March 25th after seeing unprecedented fiscal and monetary stimulus unleashed by the Fed and the Congress
Insider Monkey · 09/15 05:47
ChemoCentryx to Present at the H.C. Wainwright 22nd Annual Global Investment Conference
MOUNTAIN VIEW, Calif., Sept. 08, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at the H.C. Wainwright 22nd Annual Global Investment Conference on Tuesday, September 15, 2020 at 1:30 p.m. ET
GlobeNewswire · 09/08 13:30
Imagine Holding ChemoCentryx (NASDAQ:CCXI) Shares While The Price Zoomed 652% Higher
ChemoCentryx, Inc. (NASDAQ:CCXI) shareholders might be concerned after seeing the share price drop 20% in the last...
Simply Wall St. · 09/04 13:45
No other industry has more at stake this election than health care. Here's how pros are playing it
Investors may be overly concerned about the impact of the presidential election on health care stocks, analysts say.
CNBC.com · 08/20 13:25
Raymond James Maintains Strong Buy on ChemoCentryx, Raises Price Target to $100
Raymond James maintains ChemoCentryx (NASDAQ:CCXI) with a Strong Buy and raises the price target from $95 to $100.
Benzinga · 08/11 11:59
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CCXI. Analyze the recent business situations of ChemoCentryx through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CCXI stock price target is 76.75 with a high estimate of 100.00 and a low estimate of 63.00.
EPS
Institutional Holdings
Institutions: 239
Institutional Holdings: 53.48M
% Owned: 77.63%
Shares Outstanding: 68.89M
TypeInstitutionsShares
Increased
86
8.18M
New
62
4.89M
Decreased
42
3.94M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.52%
Pharmaceuticals & Medical Research
-1.14%
Key Executives
Chairman/Chief Executive Officer/President/Director
Thomas Schall
Chief Financial Officer/Executive Vice President/Chief Administrative Officer/Secretary/IR Contact Officer
Susan Kanaya
Treasurer
Markus Cappel
Independent Director
Thomas Edwards
Independent Director
Joseph Feczko
Independent Director
Rita Jain
Independent Director
Henry McKinnell
Independent Director
Geoffrey Parker
Independent Director
James Tyree
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About CCXI
ChemoCentryx, Inc. is a biopharmaceutical company. The Company is engaged in developing new medications targeted at inflammatory disorders, autoimmune diseases and cancer. Each of its drug candidates focuses on a specific chemoattractant receptor that selectively blocks its negative inflammatory or suppressive response, leaving the rest of the immune system intact. Its late stage compounds include Avacopan (CCX168) and CCX140. Avacopan (CCX168) is an orally administered complement inhibitor targeting the C5a receptor (C5aR), and is being developed for orphan and rare diseases, including anti-neutrophil cytoplasmic auto-antibody associated vasculitis (AAV); atypical hemolytic uremic syndrome (aHUS), and complement 3 glomerulopathy (C3G). CCX140 is an orally administered inhibitor of the chemokine receptor known as C-C chemokine receptor type 2 (CCR2), in development for diabetic nephropathy (DN), a form of chronic kidney disease (CKD), and for focal segmental glomerulosclerosis (FSGS).
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of ChemoCentryx Inc stock information, including NASDAQ:CCXI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CCXI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CCXI stock methods without spending real money on the virtual paper trading platform.